Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Subscribe

Sci. STKE, 23 April 2002
Vol. 2002, Issue 129, p. re5
[DOI: 10.1126/stke.2002.129.re5]

REVIEWS

Endocannabinoids and Neuroprotection

R. Mechoulam1*, M. Spatz3, and E. Shohami2

1Department of Medicinal Chemistry and Natural Products, Hebrew University Medical Faculty, Jerusalem 91120, Israel.
2Department of Pharmacology, Hebrew University Medical Faculty, Jerusalem 91120, Israel.
3Stroke Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, 36 Convent Drive, MSC 4128, Bethesda, MD 20892-4128, USA.

Gloss: Traumatic brain injury (TBI) causes the accumulation of harmful endogenous constituents in the brain, which may lead to secondary damage; protective mechanisms are also set in motion. Understanding the pathophysiology of secondary brain injury might lead to the development of novel therapeutic treatments for this common condition. The synthesis in the brain of the endogenous cannabinoids 2-arachidonoyl glycerol (2-AG) and anandamide is enhanced in mice and rats, respectively, after TBI and reduces brain damage. These compounds represent a new class of neuroprotective agents that have multiple mechanisms of action that may involve inhibition of transmitter release and of the inflammatory response and might improve the blood supply to the injured brain.

*Corresponding author. E-mail: mechou{at}cc.huji.ac.il

Citation: R. Mechoulam, M. Spatz, E. Shohami, Endocannabinoids and Neuroprotection. Sci. STKE 2002, re5 (2002).


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
The Highs and Lows of Cannabinoid Receptor Expression in Disease: Mechanisms and Their Therapeutic Implications.
L. K. Miller and L. A. Devi (2011)
Pharmacol. Rev. 63, 461-470
   Abstract »    Full Text »    PDF »
Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington's disease.
C. Blazquez, A. Chiarlone, O. Sagredo, T. Aguado, M. R. Pazos, E. Resel, J. Palazuelos, B. Julien, M. Salazar, C. Borner, et al. (2011)
Brain 134, 119-136
   Abstract »    Full Text »    PDF »
CB1 Cannabinoid Receptors Increase Neuronal Precursor Proliferation through AKT/Glycogen Synthase Kinase-3{beta}/{beta}-Catenin Signaling.
S. Trazzi, M. Steger, V. M. Mitrugno, R. Bartesaghi, and E. Ciani (2010)
J. Biol. Chem. 285, 10098-10109
   Abstract »    Full Text »    PDF »
NEUROSCIENCE: Stout Guards of the Central Nervous System.
R. Mechoulam and A. H. Lichtman (2003)
Science 302, 65-67
   Abstract »    Full Text »    PDF »

To Advertise     Find Products


Science Signaling. ISSN 1937-9145 (online), 1945-0877 (print). Pre-2008: Science's STKE. ISSN 1525-8882